English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

3SBio Given SFDA Permission for Phase III Trial of Anti-Rejection Drug

Jun. 27, 2012

Isotechnika Pharma announced on June 28, 2012 that 3SBio Inc., a leading China-based biotechnology company, has received approval from the SFDA to conduct a multi-center Phase III trial of Isotechnika’s voclosporin in China.
According to the approved protocol, this will be a Phase III, randomized, multi-center, concentration-controlled and comparison study in kidney transplant patients. Patient enrollment is expected to begin in the fall of 2012.